Therapy

Give a glycoprotein IIb/ IIIa antagonist  ^a

Why?

• Glycoprotein IIb/ IIIa antagonists used during PTCA reduce death, myocardial infarction and urgent revasculariation, but increase major bleeding. ^a
• Glycoprotein IIb/ IIIa antagonists used during PTCA with stenting reduce death, myocardial infarction and urgent revasculariation, but do not clearly increase major bleeding. ^a

Glycoprotein IIb/ IIIa antagonists reduce death, myocardial infarction and urgent revascularisation

Patient	Treatment	Comparison	Outcome	CER	OR (95% CI)	NNT (95% CI)
urgent or elective angioplasty  a	glycoprotein IIb/ IIIa antagonists	placebo	death or MI at 6 months	11.1%	0.78 (0.65 to 0.94)	45 (28 to 170)
urgent or elective angioplasty a			urgent revascularisation at 6 months	20%	0.85 (0.74 to 0.97)	40 (22 to 200)
urgent or elective angioplasty a			major bleeding at 30 days	4.3	1.42 (1.20 to 1.67)	-58 (-120 to -37)
urgent or elective angioplasty with stenting a	glycoprotein IIb/ IIIa antagonists	placebo	major bleeding at 6 months	11.5%	0.54 (0.44 to 0.67)	22 (17 to 32)
			urgent revascularisation at 30 days	2.1%	0.62 (0.39 to 0.97)	130 (79 to 1600)